A multicenter study of pediatric patients treated with fidaxomicin for C difficile found over half were cured by two weeks, and only one in five had a recurrence within two months.
FDA approved the first biannual injectable PrEP option, Yeztugo (lenacapavir), after studies showed it prevented HIV infection in over 99.9% of participants.
New 2024 EULAR recommendations offer evidence-based guidance for the use of antirheumatic drugs during pregnancy, lactation, and conception planning in patients with rheumatic and musculoskeletal diseases.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
The FDA has approved enflonsia, a fixed-dose monoclonal antibody, for preventing RSV lower respiratory tract disease in infants during their first season.
First-year university students who adopted unhealthy habits such as poor diet, vaping, and reduced brushing frequency experienced significant declines in self-reported oral health over 6 months.